Topics

Immunotherapy and Neurological Adverse Events

Cancer Immunotherapy Neurodegeneration Chronic Inflammation Cellular Degeneration

Cancer immunotherapy can cause neurologic immune-related adverse events when immune activation extends beyond the tumor and injures the central or peripheral nervous system. These toxicities are less common than dermatologic, gastrointestinal, or endocrine adverse events, but they can progress rapidly and leave substantial disability. Reported syndromes include encephalitis, aseptic meningitis, central nervous system demyelination, cranial and peripheral neuropathies, myasthenia gravis, and inflammatory myopathy, with clinically important overlap between neuromuscular presentations. Onset may occur early after checkpoint exposure, yet delayed presentations make a fixed surveillance window unreliable. Most evidence comes from pharmacovigilance, case series, and retrospective cohorts rather than randomized toxicity studies. The expanding use of checkpoint inhibitors makes early recognition increasingly important because a new neurologic symptom may otherwise be attributed to metastasis, infection, metabolic disturbance, or cancer progression[1][2][3].

Checkpoint blockade removes inhibitory signals that normally limit T-cell activation. PD-1/PD-L1 and CTLA-4 inhibition can expand autoreactive clones, increase inflammatory cytokines, enhance autoantibody production, and expose antigenic overlap between tumor and neural tissue. Tissue-specific mechanisms probably differ: antibody and complement may dominate at the neuromuscular junction, cytotoxic T cells may mediate encephalitis or myositis, and activated lymphocytes and macrophages can damage myelin. Concurrent myocarditis with myositis or myasthenic features is particularly important because it can turn a focal complaint into a multisystem emergency. Pre-existing autoimmunity may increase vulnerability, but severe events also occur without a known neurologic disorder. The broad mechanistic spectrum explains why no single laboratory marker confirms the diagnosis and why normal imaging or cerebrospinal fluid cannot reliably exclude an immune-mediated syndrome at an early stage[1][2].

Evaluation should begin urgently when weakness, ptosis, dysphagia, dyspnea, confusion, seizure, sensory loss, ataxia, or a new headache develops after immunotherapy. The work-up is syndrome-directed and may include magnetic resonance imaging, cerebrospinal fluid analysis, electrodiagnostic testing, creatine kinase and cardiac assessment, autoantibody testing, and studies for infection or malignancy. Suspected severe toxicity generally requires holding checkpoint treatment and initiating corticosteroids; intravenous immunoglobulin, plasma exchange, or other immunosuppression may be added for selected refractory or antibody-mediated syndromes. Antimicrobial coverage may be appropriate until infection is excluded in encephalitic presentations. Respiratory and cardiac monitoring is essential in myasthenia-myositis overlap. Rechallenge decisions must weigh cancer benefit against phenotype, severity, recovery, and availability of alternative therapy[2][3].

Important gaps include inconsistent case definitions, underreporting of mild events, and limited prospective biospecimen collection. Multicenter registries should link phenotype, timing, checkpoint class, tumor response, treatment, and long-term neurologic outcome. Neurologic adverse events also need adjudication that distinguishes definite immune toxicity from plausible and unrelated syndromes. Paired blood and cerebrospinal fluid studies could reveal pathogenic T-cell receptors, neural autoantibodies, cytokines, or genetic susceptibility before irreversible injury. Better evidence is needed to determine the minimum effective immunosuppression and whether selected patients can safely resume treatment. Rehabilitation needs and persistent cognitive or neuromuscular deficits should be measured rather than inferred from survival. The immediate clinical priority remains disciplined syndrome recognition and rapid exclusion of mimics; the scientific priority is to uncouple antitumor immunity from neural autoimmunity without broadly eliminating the therapeutic immune response[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L027 Antiviral Compound Library
Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs. MCE designs a unique collection of 1,237 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Disease Focused Libraries

104
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L054 Endoplasmic Reticulum Stress Compound Library
Endoplasmic reticulum (ER) contributes to the production and folding of approximately one third of cellular proteins, and is thus inextricably linked to the maintenance of cellular homeostasis and the fine balance between health and disease. However, some adverse factors negatively impact ER functions and protein synthesis, resulting in the activation of Endoplasmic reticulum stress (ER stress, ERS) and unfolded protein response (UPR) signaling pathways. The UPR is triggered when ER protein folding capacity is overwhelmed by cellular demand and the UPR initially aims to restore ER homeostasis and normal cellular functions. However, if this fails, then the UPR triggers cell death. Chronic ER stress and defects in UPR signaling are emerging as key contributors to a growing list of human diseases, including diabetes, neurodegeneration and cancer. MCE Endoplasmic Reticulum Stress Compound Library contains 379 ER stress-related compounds that mainly target PERK, IRE1, ATF6, etc. MCE ER stress library is a useful tool for researching ER stress and related diseases.

Signaling Pathway Targeting Libraries

85
HY-L047 Endocrinology Compound Library
The endocrine system is a chemical messenger system comprising feedback loops of the hormones released by internal glands of an organism directly into the circulatory system, regulating distant target organs. Hormones are chemicals that serve to communicate between organs and tissues for physiological regulation and behavioral activities. Hormones affect distant cells by binding to specific receptor proteins in the target cell, resulting in a change in cell function. The endocrine system is concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Irregulated hormone release, inappropriate response to signaling or lack of a gland can lead to endocrine disease. MCE offers a unique collection of 908 endocrinology related compounds targeting varieties of hormone receptors such as thyroid hormone receptor, TSH receptor, GNRH receptor, adrenergic receptor, etc. MCE Endocrinology Compound Library is a useful tool for the discovery of endocrinology drugs.

Disease Focused Libraries

83
HY-L062 Neurotransmitter Receptor Compound Library
Neurotransmitter (NT) receptors, also known as neuroreceptors, are a broadly diverse group of membrane proteins that bind neurotransmitters for neuronal signaling. There are two major types of neurotransmitter receptors: ionotropic and metabotropic. Ionotropic receptors are ligand-gated ion channels, meaning that the receptor protein includes both a neurotransmitter binding site and an ion channel. The binding of a neurotransmitter molecule (the ligand) to the binding site induces a conformational change in the receptor structure, which opens, or gates, the ion channel. The term “metabotropic receptors” is typically used to refer to transmembrane G-protein-coupled receptors. Metabotropic receptors trigger second messenger-mediated effects within cells after neurotransmitter binding. In some neurological diseases, the neurotransmitter receptor itself appears to be the target of the disease process. Many neuroactive drugs act by modifying neurotransmitter receptors. A better understanding of neurotransmitter receptor changes in disease may lead to improvements in therapy. MCE designs a unique collection of 2,593 compounds targeting a variety of neurotransmitter receptors. MCE Neurotransmitter Receptor Compound Library is a useful tool for neurological diseases drug discovery.

Signaling Pathway Targeting Libraries

83
HY-L118 Sodium Channel Blocker Library
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion. MCE offers a unique collection of 199 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Signaling Pathway Targeting Libraries

83
HY-L140 Withdrawn Drug Compound Library
Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug. Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications. MCE has sorted out 232 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Drug Repurposing Series

83
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L225 Cardiotoxic Compound Library
Drug development is both expensive and time-consuming, with approximately one-third of drug discontinuations caused by severe adverse drug reactions (ADRs). Among these, drug-induced cardiotoxicity (DICT) is one of the primary reasons for late-stage clinical drug failures and market withdrawals. To date, cardiotoxicity has been observed in multiple drug classes, such as anticancer drugs, antipsychotics, antidepressants, antibiotics, and neurodegenerative disease medications. To reduce cardiac ADRs, it is crucial to determine the clinical relevance of DICT to treatment, elucidate the underlying molecular mechanisms, identify reliable biomarkers, and develop new diagnostic and therapeutic approaches. MCE offers 260 cardiotoxicity compounds, including some FDA-approved drugs as well as inhibitors/blockers of the hERG potassium channel.
83
HY-L255 Dipeptide Compound Library
Dipeptide compounds have attracted extensive attention in drug discovery and life science research due to their simple structures, ease of modification, and favorable biocompatibility. As small peptides composed of two amino acids, dipeptides exhibit diverse biological activities, including anti-inflammatory, antioxidant, antimicrobial, anticancer, and immunomodulatory effects, showing significant application potential in metabolic disorders, neurological diseases, and cancer research. Compared with traditional small molecules, dipeptide compounds possess favorable target-binding properties and high structural plasticity, making them valuable tools for drug screening and mechanism studies. The MCE Dipeptide Compound Library contains 72 dipeptide compounds and can be applied to peptide drug discovery and development.

Structure Classified Libraries

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-P0128 β-Amyloid (25-35)
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
Amyloid-β  
51
HY-N2332A Methyllycaconitine citrate
Methyllycaconitine (MLA) citrate is a blood-brain barrier-permeable antagonist of α7 nicotinic acetylcholine receptor (α7nAChR) with an IC50 of 2 nM. Methyllycaconitine citrate inhibits Aβ25-35-induced autophagy by restoring the mTOR pathway, and prevents reactive oxygen species (ROS) production, microglial activation, reduced dopamine uptake, loss of dopaminergic terminals and catecholamine secretion. Methyllycaconitine citrate induces hippocampal glutamate efflux, enhances long-term potentiation, and improves memory acquisition. Methyllycaconitine citrate can be used in research related to Alzheimer's disease, cerebral palsy, Parkinson's disease and schizophrenia.
nAChR   Autophagy   Reactive Oxygen Species (ROS)   mTOR  
Alzheimer's Disease  
50
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-12495A ISRIB
ISRIB is a brain-penetrant inhibitor of integrated stress response (ISR). Persistent activation of the ISR has been linked to the development of several neurological disorders as ISR represses translation through inhibiting eIF2B. ISRIB inhibits the ISR by promoting the nucleotide exchange activity of eIF2B and recovering the translation, and thus can be used for neurological disorders research.
Biochemical Assay Reagents   Eukaryotic Initiation Factor (eIF)  
Neurological, Eye or Ear Disease  
37
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-D0836 EDTA dipotassium dihydrate
EDTA dipotassium dihydrate is a metal ion chelator that forms stable and water-soluble chelates with a variety of metal ions. EDTA dipotassium is commonly used as a blood anticoagulant, which can effectively prevent blood coagulation and maintain the morphology and function of cells in blood samples. In the industrial field, EDTA dipotassium can be used to remove the adverse effects of metal ions and prevent oxidation and deterioration caused by metal ions.
DNA/RNA Synthesis  
33
HY-B0282 Acetylcholine chloride
Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent and BBB-permeable cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs). Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro.
nAChR   Calcium Channel   Endogenous Metabolite  
Breast Cancer   Viral Infection   Alzheimer's Disease  
33
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-A0106 Levamisole
Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC50=300 μM) and α3β4 (EC50=100 μM) subtype of nAChRs. Orally active.
nAChR   Parasite  
Inflammation or Immune System Disease   Colorectal Cancer   Liver Cancer   HIV Infection   Parasitic Infection   SARS-CoV-2 Infection  
17
HY-14564A GTS-21 dihydrochloride
GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor (α7-nAChR) agonist with anti inflammatory and cognition enhancing activities. GTS-21 dihydrochloride is also a α4β2 (Ki=20 nM for humanα4β2) and 5-HT3A receptor (IC50=3.1 μM) antagonist.
nAChR   5-HT Receptor  
Inflammation or Immune System Disease   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease  
17
HY-13780 Vinblastine sulfate
Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC50 of 8.9 μM.
Microtubule/Tubulin   nAChR   Autophagy  
Lung Cancer   Prostate Cancer   Viral Infection   Depression   Parkinson's Disease  
17
HY-12560A PNU-282987
PNU-282987 is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC50 of 154 nM. PNU-282987 is also a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM. PNU-282987 can be used for the research of central and peripheral nervous systems.
nAChR   5-HT Receptor  
Alzheimer's Disease   Parkinson's Disease  
15
HY-15136 Lonafarnib
Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria.
Farnesyl Transferase   Tau Protein   RSV   Akt   Ras   Bcl-2 Family   STAT   nAChR   Apoptosis   Autophagy  
Melanoma   Viral Infection   Alzheimer's Disease  
14
HY-B1945 DEHP
DEHP (Bis(2-ethylhexyl) phthalate) is a widely used plasticizer, which has orally active. DEHP can produce a wide spectrum of toxic effects on organisms including neurotoxicity, liver toxicity, immunotoxicity, and reproductive toxicity.
Environmental Pollutants   Endogenous Metabolite  
Metabolic or Endocrine Disease  
13
HY-135867 NHC-triphosphate
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
CHIKV   Endogenous Metabolite   Enterovirus   HCV   Topoisomerase   SARS-CoV  
Infection  
11
HY-135867A NHC-triphosphate tetrasodium
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
CHIKV   Endogenous Metabolite   Enterovirus   HCV   Topoisomerase  
Infection  
11
HY-B1777A Spermine tetrahydrochloride
Spermine tetrahydrochloride is a polyamine nitric oxide donor that can provide nitric oxide to platelets and inhibit platelet activation to a certain extent concentration-dependently. Spermine tetrahydrochloride occurs in mammalian tissues, plants, bacteria, ribosomes and bacteriophage. Spermine tetrahydrochloride inhibits primary human embryo lung fibroblasts in vitro. Spermine is a natural antioxidant and anti-inflammatory agent. Spermine is known to inhibit some bacterial cultures, especially strains of Staphylococcus aureus. Spermine induces neurotoxicity in the striarum dose-dependently. Spermine can reversibly inhibits DNA synthetic response, mixed lymphocyte response and the induction of cytolytic lymphocyte response in primary cultures of murine spleen cells.
Endogenous Metabolite   Bacterial   Reactive Oxygen Species (ROS)   DNA/RNA Synthesis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Prostate Cancer   Bacterial Infection  
11
HY-P1240B MOG (35-55) acetate
MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate is a minor component of CNS myelin. MOG (35-55) (acetate) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (acetate) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (acetate) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate can be used for experimental autoimmune encephalomyelitis (EAE) modeling.
Others  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
9
HY-P1240A MOG (35-55) TFA
MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling.
Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
9
HY-P1240 MOG (35-55) mouse, rat
MOG (35-55) mouse, rat (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) is a minor component of CNS myelin. MOG (35-55) mouse, rat has encephalitogenic activity and induces T cell proliferative. MOG (35-55) mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) mouse, rat (MOG (35-55)) can be used for experimental autoimmune encephalomyelitis (EAE) modeling.
Endogenous Metabolite  
Epilepsy   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
9
HY-B0277 Vidarabine
Vidarabine (Ara-A) is a Purine nucleoside derivative and Antiviral agent. The triphosphate derivative of Vidarabine competitively inhibits DNA polymerase, incorporates into the terminus of elongating DNA molecules, and interferes with the early steps of viral DNA synthesis. Vidarabine inhibits the replication of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus and vaccinia virus, reduces viral shedding, and accelerates skin healing. Vidarabine is metabolized to arabinosyl hypoxanthine, causes minimal impairment of corneal wound healing in rabbit models, and is associated with recurrence of herpes simplex encephalitis. Vidarabine can be used in the research of herpetic keratoconjunctivitis, herpes simplex encephalitis, herpetic uveitis, and chronic active hepatitis associated with hepatitis B virus.

Source: Streptomyces

Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis   HSV   VZV   CMV   EBV  
Cytomegalovirus Infection   HSV Infection  
8
HY-101878 Texas Red
Texas Red (Sulforhodamine 101) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations.
Fluorescent Dye  
Neurological, Eye or Ear Disease  
8
HY-B1395 Mecamylamine hydrochloride
Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine hydrochloride is also a ganglionic blocker. Mecamylamine hydrochloride can across the blood-brain barrier. Mecamylamine hydrochloride can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area.
nAChR   Histamine Receptor  
Viral Infection   Depression   Cardiovascular Disease   Parkinson's Disease   Obesity  
8
HY-B0489 Arecoline hydrobromide
Arecoline hydrobromide, a naturally brain-penetrant and orally active occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline hydrobromide exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline hydrobromide also can induce oxidative stress.
mAChR   nAChR  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Parasitic Infection  
7
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-N2364 Arecoline
Arecoline, a naturally brain-penetrant and orally active occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline also can induce oxidative stress.
mAChR   nAChR  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-P0168A Cibinetide acetate
Cibinetide (ARA290) acetate is an erythropoietin (EPO) derivative that acts as a specific agonist of the erythropoietin/CD131 heteroreceptor. ICibinetide acetate can be used in the research of neurological disorders.
Transmembrane Glycoprotein  
6
HY-B0739A Citicoline sodium
Citicoline sodium is an endogenous intermediate in the synthesis of phosphatidylcholine which is a component of cell membranes. Citicoline sodium inhibits reactive oxygen species (ROS) and apoptosis. Citicoline sodium can be used for neurological disease and hearing loss study.

Source: Widespread

Endogenous Metabolite   Apoptosis   Reactive Oxygen Species (ROS)   Caspase  
Cancer   Digestive System Disease   Neurodegenerative Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
5
HY-B0739 Citicoline
Citicoline is an endogenous intermediate in the synthesis of phosphatidylcholine which is a component of cell membranes. Citicoline inhibits reactive oxygen species (ROS) and apoptosis. Citicoline can be used for neurological disease and hearing loss study.

Source: Widespread

Apoptosis   Endogenous Metabolite   Reactive Oxygen Species (ROS)   Caspase  
Digestive System Disease   Neurodegenerative Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
5
HY-P9901 Ipilimumab
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.

Species: Human

CTLA-4  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Metastatic Melanoma  
5
HY-113402A Gamma-glutamylcysteine TFA
Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
Interleukin Related   TNF Receptor   Endogenous Metabolite   AMPK   Sirtuin   STAT   PI3K   NF-κB   JAK   p38 MAPK   JNK   Akt   Apoptosis   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Inflammatory Bowel Disease  
4
HY-W755425 Senktide TFA
Senktide TFA is a potent, selective agonist of the neuromedin K3 (NK3) receptor (EC50=0.5-3 nM). Senktide TFA less potently agonizes the NK1 receptor (EC50=35 µM). Senktide TFA is promising for research of neurological disease.
Neurokinin Receptor  
Neurological, Eye or Ear Disease  
3
HY-P1812A AUNP-12 TFA
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
PD-1/PD-L1  
Cancer  
3
HY-101889 Cresyl Violet perchlorate
Cresyl Violet perchlorate is a red fluorescent stain, which can be used to stain neurons.
Fluorescent Dye  
Neurological, Eye or Ear Disease  
3
HY-P1812 AUNP-12
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer  
3
HY-B0883 3,6-Diaminoacridine hemisulfate
3,6-Diaminoacridine hemisulfate is a multifunctional acridine compound. 3,6-Diaminoacridine hemisulfate is an acridine dye and also a DNA inserter. 3,6-Diaminoacridine hemisulfate is a potent broad-spectrum antibacterial agent. Its mechanism is to insert into bacterial DNA, interfering with replication and transcription, leading to bacterial lysis. 3,6-Diaminoacridine hemisulfate is a Kir3.2 potassium channel blocker and can be used to study the neurological phenotype of Down syndrome. 3,6-Diaminoacridine hemisulfate can penetrate the stratum corneum of the skin and accumulate in the cell nucleus. Long-term exposure may induce skin cancer or other malignant tumors.
Bacterial   Fluorescent Dye   Potassium Channel   DNA/RNA Synthesis  
Cancer   Infection   Neurological, Eye or Ear Disease  
3
HY-108829A Abatacept (powder)
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Species: Human

CTLA-4  
Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Rheumatoid Arthritis  
3
HY-101888 Cresyl Violet acetate
Cresyl Violet acetate is a dye, which can be used to stain neurons.
Fluorescent Dye  
Neurological, Eye or Ear Disease  
3
HY-P99132 Anti-Mouse CTLA-4 Antibody (9D9)
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8+ T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma.

Species: Mouse

CTLA-4  
Inflammation or Immune System Disease   Colorectal Cancer   Melanoma  
3
HY-P99037 Nipocalimab
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases.

Species: Human

Fc Receptor (FcR)  
Myasthenia gravis   Rheumatoid Arthritis  
3
HY-108829 Abatacept
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Species: Human

CTLA-4  
Lung Cancer   Melanoma   SARS-CoV-2 Infection   Rheumatoid Arthritis  
3
HY-N5077B Sinapine hydroxide
Sinapine hydroxide is an alkaloid isolated from seeds of the cruciferous species. Sinapine hydroxide exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine hydroxide is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
Cholinesterase (ChE)   P-glycoprotein  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
2
HY-N0450 Sinapine thiocyanate
Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
P-glycoprotein   Cholinesterase (ChE)  
Ovarian Cancer   Alzheimer's Disease   Parkinson's Disease  
2
HY-N5077 Sinapine
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
Cholinesterase (ChE)   P-glycoprotein  
Inflammation or Immune System Disease   Ovarian Cancer   Alzheimer's Disease   Parkinson's Disease  
2
HY-Y0808 Dimethyl succinate
Dimethyl succinate is an orally active cell permeable succinate analogue. Dimethyl succinate can disrupt the TCA cycle by elevating intracellular succinate levels, leading to reduced protein synthesis and impairs myogenic differentiation. Dimethyl succinate can induce apoptosis. Dimethyl succinate can decrease maximal cellular respiration and reserve capacity. Dimethyl succinate can rescue synapse loss in AD. Dimethyl succinate can be used for the researches of metabolic and neurological disease.
Environmental Pollutants   Apoptosis  
Metabolic or Endocrine Disease   Alzheimer's Disease  
2
HY-W019870A Glufosinate
Glufosinate, a phosphinic acid analogue of glutamic acid, is a herbicide which is converted by plant cells into PT (L-phosphinothricin). Glufosinate exerts neurotoxic activity.

Source: Streptomyces viridochromogenes

Herbicide  
Neurological, Eye or Ear Disease  
1
HY-135867F NHC-diphosphate triammonium
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form. NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
CHIKV   Endogenous Metabolite   Enterovirus   HCV   Topoisomerase   SARS-CoV  
Infection  
1
HY-135867D NHC-diphosphate
NHC-diphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form. NHC is a pyrimidine ribonucleoside and behaves as a potent anti-virus agent. NHC effectively inhibits the replication of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV).
CHIKV   Endogenous Metabolite   Enterovirus   HCV   Topoisomerase   SARS-CoV  
Infection  
1
HY-P3255 DA-JC4
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.
Insulin Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
1
HY-Y0304S Dibutyl phthalate-3,4,5,6-d4
Dibutyl phthalate-3,4,5,6-d4 is the deuterium labeled Dibutyl phthalate. Dibutyl phthalate is a commonly used plasticizer commonly found in some food packaging materials, personal care products, and the coating of oral medications. May cause toxicity and adverse neurobehavioral effects.
Isotope-Labeled Compounds  
Cancer   Neurological, Eye or Ear Disease  
1
HY-B1945R DEHP (Standard)
DEHP (Standard) is the analytical standard of DEHP. This product is intended for research and analytical applications. DEHP (Bis(2-ethylhexyl) phthalate) is a widely used plasticizer, which has orally active. DEHP can produce a wide spectrum of toxic effects on organisms including neurotoxicity, liver toxicity, immunotoxicity, and reproductive toxicity.
Reference Standards   Endogenous Metabolite  
Metabolic or Endocrine Disease  
1
HY-P4270 Met-Arg-Phe-Ala
Met-Arg-Phe-Ala is a peptide. Met-Arg-Phe-Ala also is a potent competitive inhibitor for enkephalin-generating endopeptidase (EGE). Met-Arg-Phe-Ala can be used for the research of neurological disease.
Neprilysin  
Neurological, Eye or Ear Disease  
1
HY-138903 L-Homocysteic acid
L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC50: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders.
iGluR  
Neurological, Eye or Ear Disease  
1
HY-121192 Capillarisin
Capillarisin, as a constituent from Artemisiae Capillaris herba, is found to exert anti-inflammatory and antioxidant properties. Capillarisin can be used for the research of asthma-mediated complications and can be a potential neuroprotectant against bupivacaine-induced neurotoxicity.
Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
1
HY-W250122 Glutamic acid sodium salt
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders.
Biochemical Assay Reagents   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   Apoptosis   HSP   Bcl-2 Family  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-Z0283 Benzamide
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature.
Endogenous Metabolite   PARP  
Neurological, Eye or Ear Disease   Breast Cancer   Ovarian Cancer  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-P990008 Atrosab
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

TNF Receptor   Apoptosis  
Experimental Autoimmune Encephalomyelitis   Multiple Sclerosis   Experimental Autoimmune Encephalomyelitis   Rheumatoid Arthritis  
1
HY-109521A Manganese chloride tetrahydrate, molecular biology grade,≥99.0% (KT)
Manganese chloride (tetrahydrate), molecular biology grade,≥99.0% (KT) is an orally active and a blood-brain barrier penetrant compound. It affects the activities of multiple enzymes in cells, such as regulating the activities of histone acetyltransferase (HAT) and histone deacetylase (HDAC), thereby affecting gene expression. It has multiple activities such as neurotoxicity, embryotoxicity, and reproductive toxicity. It is currently mainly used in neurodegenerative diseases and toxicology research.
Biochemical Assay Reagents   Histone Acetyltransferase   HDAC  
Neurological, Eye or Ear Disease  
1
HY-P99113 Inebilizumab
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

Species: Human

ADC Antibodies   CD19  
Myasthenia gravis   Multiple Sclerosis  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-B0137AS Prilocaine-d7 hydrochloride
Prilocaine-d7 (hydrochloride) is deuterium labeled Prilocaine (hydrochloride). Prilocaine hydrochloride, an amino amide, is a Na, K-ATPase inhibitor. Prilocaine has neurotoxic effects.
Isotope-Labeled Compounds   Na+/K+ ATPase  
Neurological, Eye or Ear Disease  
/
HY-P990031 Dargistotug
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-100966S BD-1008-d5 dihydrobromide
BD-1008-d5 dihydrobromide is the deuterium labeled BD-1008 dihydrobromide (HY-100966). BD-1008 dihydrobromide is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 dihydrobromide has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM). BD-1008 dihydrobromide significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 dihydrobromide blocks the self-administration behavior of σ agonists.BD-1008 dihydrobromide can be used for the study of addiction therapy that target the σ receptor.
Isotope-Labeled Compounds   Sigma Receptor  
Neurological, Eye or Ear Disease  
/
HY-P11244 150D4
150D4 is an efficient, selective, and blood-brain barrier penetrable EphA4 agonist. 150D4 has excitatory activity and neuroprotective effects. 150D4 can be used for research on neurological conditions.
Ephrin Receptor  
Neurological, Eye or Ear Disease  
/
HY-P3275 β-Amyloid (17-40)
β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-N6619 Lycoramine hydrobromide
Lycoramine hydrobromide is a blood-brain barrier-penetrating Acetylcholinesterase inhibitor and Galanthamine (HY-76299) derivative. Lycoramine hydrobromide induces Amyloid-beta plaque clearance. Lycoramine hydrobromide induces reversal of cognitive decline and memory improvement. Lycoramine hydrobromide can be used for research on Alzheimer's disease and myasthenia gravis.
Cholinesterase (ChE)   Amyloid-β   Drug Derivative  
Alzheimer's Disease   Myasthenia gravis  
/
HY-W754608 EIDD 1931-13C,15N2
EIDD 1931-13C,15N2 (β-D-N4-Hydroxycytidine-13C,15N2) is the 13C- and 15N-labeled EIDD 19312 (HY-125033). EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent?anti-virus agent. EIDD-1931 effectively inhibits the replication activity of?venezuelan equine encephalitis?virus (VEEV),?Chikungunya?virus (CHIKV) and?hepatitis?C virus (HCV)
Isotope-Labeled Compounds   Enterovirus   SARS-CoV   Topoisomerase   CHIKV   HCV  
Infection  
/
HY-Y0304S2 Dibutyl phthalate-13C2
Dibutyl phthalate-13C2 is the 13C-labeled Dibutyl phthalate (HY-Y0304). Dibutyl phthalate is a commonly used plasticizer commonly found in some food packaging materials, personal care products, and the coating of oral medications. May cause toxicity and adverse neurobehavioral effects.
Isotope-Labeled Compounds   Environmental Pollutants  
Cancer   Neurological, Eye or Ear Disease  
/
HY-W753485 Profenofos-d3
Profenofos-d3 is the deuterium labeled Profenofos (HY-B0832). Profenofos is an insecticida used on field crops, vegetables, and fruit crops. Profenofos is an acetylcholinesterase (AChE) inhibitor, with neurotoxicity.
Isotope-Labeled Compounds   Insecticide   Cholinesterase (ChE)  
Neurological, Eye or Ear Disease  
/
HY-W753956 Iminostilbene-d10
Iminostilbene-d10 is the deuterium labeled Iminostilbene (HY-N7064). Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.
Isotope-Labeled Compounds   COX   HIF/HIF Prolyl-Hydroxylase   Pyruvate Kinase   TNF Receptor   Interleukin Related   STAT   NO Synthase  
Inflammation or Immune System Disease  
/
HY-12355S Siponimod-d11
Siponimod-d11 (BAF-312-d11) is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod can be used in research related to multiple sclerosis.
Isotope-Labeled Compounds   Potassium Channel   LPL Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-B0167E Salicylic acid Sterile Solution (1 mg/ml)
Salicylic acid Sterile Solution (1 mg/mL) is a sterile solution suitable for plant culture. Salicylic acid (HY-B0167) is a weak acid that, once inside the plant, can activate growth regulators such as nitric oxide, thereby influencing plant growth and development. Salicylic acid can also regulate plant cell metabolism and membrane permeability, improving the plant's resistance to adverse conditions.
Biochemical Assay Reagents  
/
HY-W711807 D-Arabitol-d7
D-Arabitol-d7 is the deuterium labeled D-Arabitol (HY-N3686). D-Arabitol is a polyol and its accumulation may cause a neurotoxic effect in human.
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-B1971S Deltamethrin-d5
Deltamethrin-d5 is the deuterium labeled Deltamethrin. Deltamethrin (Decamethrin), a neurotoxic pyrethroid insecticide, produces a reversible sequence of motor symptoms in rats involving hind limb rigidity and choreoathetosis.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer  
/
HY-N15717A (threo) 1',2'-Dihydroxyasarone
(threo) 1',2'-Dihydroxyasarone is an antioxidant found in the roots of Acorus tatarinowii. (threo) 1',2'-Dihydroxyasarone is promising for research of neurological diseases such as dementia.
Drug Metabolite  
Neurological, Eye or Ear Disease  
/
HY-P991768 Anti-Eastern equine encephalitis virus E2 protein Antibody (EEEV-3)
Anti-Eastern equine encephalitis virus E2 protein Antibody (EEEV-3) reacts with the B domain of the E2 glycoprotein on the eastern equine encephalitis virus (EEEV). Anti-Eastern equine encephalitis virus E2 protein Antibody (EEEV-3) exhibits a modest inhibition of viral attachment to the plasma membrane of the cells. Recommend Isotype Controls: Mouse IgG2c kappa, Isotype Control (HY-P99981).

Species: Virus

Virus Protease  
Viral Infection  
/
HY-P991536 KHK6640
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease.

Species: Human

Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-N0450R Sinapine thiocyanate (Standard)
Sinapine (thiocyanate) (Standard) is the analytical standard of Sinapine (thiocyanate). This product is intended for research and analytical applications. Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
Reference Standards   P-glycoprotein   Cholinesterase (ChE)  
Cancer  
/
HY-103684 RT-NH2
RT-NH2 is a RealThiol prototype without the carboxylic acid groups. RT-NH2 is fairly hydrophobic and cannot distribute in the nucleus, which is a hallmark of protein binding for fluorescent probe.
Fluorescent Dye  
Neurological, Eye or Ear Disease  
/
HY-N16662A threo-Anethole glycol
threo-Anethole glycol (Compound 12) is an aromatic diol compound found in Foeniculi Fructus. threo-Anethole glycol has potential antioxidant activity and can be used for the researches of inflammation, cardiovascular and neurological disease.
Others  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P990229 Anti-Rat IgG2b Antibody (RG7/11.1)
Anti-Rat IgG2b Antibody (RG7/11.1) is an anti-rat IgG2b monoclonal antibody. Anti-Rat IgG2b Antibody (RG7/11.1) can be used for research on neurological and infection conditions such as temporal lobe epilepsy (TLE). Anti-Rat IgG2b Antibody (RG7/11.1) is often used for the same type control.

Species: Mouse

Others  
Infection   Neurological, Eye or Ear Disease  
/
HY-N11234A (Z)-γ-Bisabolene
(Z)-γ-Bisabolene is a monocyclic bisabolane-type sesquiterpene hydrocarbon found in the essential oil of Galinsoga parviflora, acting as a mosquito larvicide and oviposition deterrent. (Z)-γ-Bisabolene induces acute toxicity in larvae of six mosquito species. (Z)-γ-Bisabolene deters oviposition in gravid females of six mosquito species. (Z)-γ-Bisabolene can be used for the research of malaria, dengue, japanese encephalitis, zika virus.
Insecticide  
Insecticide  
/
HY-B1315S Carbaryl-d3
Carbaryl-d3 is the deuterium labeled Carbaryl (HY-B1315). Carbaryl is the inhibitor for acetylcholinesterase that inhibits the degradation of acetylcholine in the synaptic cleft, leads to the accumulation of acetylcholine and causes neurotoxicity. Carbaryl can be used as an insecticide. X
Isotope-Labeled Compounds   Insecticide   Cholinesterase (ChE)   Reactive Oxygen Species (ROS)   Apoptosis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P5642 Retrocyclin-101
Retrocyclin-101 (RC-101) is a synthetic cyclic θ-defensin, a broad-spectrum antimicrobial peptide with anti-pathogen (covering viruses, bacteria and fungi) activity and anti-inflammatory activity. Retrocyclin-101 exhibits significant inhibitory activity against HIV, SARS-CoV-2, flaviviruses, influenza viruses, HSV-1/2, Staphylococcus aureus and others. Retrocyclin-101 inhibits TLR4 and TLR2-mediated signal transduction and reduces pro-inflammatory cytokine expression.
Bacterial   HSV   Fungal   Influenza Virus   Toll-like Receptor (TLR)   Flavivirus   Ser/Thr Protease   SARS-CoV   HIV  
Infection   Inflammation or Immune System Disease  
/
HY-N2511S Trimyristin--d15
Trimyristin--d15 is the d15-labeled Trimyristin (HY-N2511). Trimyristin is an orally active compound. Trimyristin can be isolated from the seeds of nutmeg (Myristica fragrans). Trimyristin inhibits the activities of acetylcholinesterase (AChE), ACP and ALP, with IC50 values of 0.11, 0.16 and 0.18 mM, respectively. Trimyristin exerts competitive-noncompetitive inhibition on acetylcholinesterase, uncompetitive inhibition on ACP, and competitive/noncompetitive inhibition on ALP. Trimyristin restores the downregulated acetylcholinesterase concentration in the cerebral cortex of rats exposed to sodium arsenite. Trimyristin can be used in studies related to fascioliasis and neurotoxicity.
Isotope-Labeled Compounds   Cholinesterase (ChE)   Phosphatase  
Neurological, Eye or Ear Disease   Parasitic Infection  
/
HY-P4623 Penta-alanine
Penta-alanine (Penta-L-alanine) is a petide. Penta-alanine can be used for neurological disease research.
Others  
Neurological, Eye or Ear Disease  
/
HY-P11409 Prion Protein (118-135), human
Prion Protein (118-135), human is the 118-135 fragment of human prion protein. Prion Protein (118-135), human induces Apoptosis. Prion Protein (118-135), human stimulates caspase-3 and -9 activities. Prion Protein (118-135), human is cytotoxic to retinal neurons. Prion Protein (118-135), human exerts neurotoxic effects.
Apoptosis   Caspase  
Neurological, Eye or Ear Disease  
/
HY-N16662 erythro-Anethole glycol
erythro-Anethole glycol (Compound 11) is an aromatic diol compound found in Foeniculi Fructus. erythro-Anethole glycol has potential antioxidant activity and can be used for the researches of inflammation, cardiovascular and neurological disease.
Others  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-B0356G Ciprofloxacin (GMP)
Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity.
Bacterial   Topoisomerase   Akt   β-catenin  
Digestive System Disease   Periodontal Disease  
/
HY-P10035 β Amyloid(28-35) human
β Amyloid(28-35) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid oligomers are neurotoxic, and β Amyloid(28-35) human can interact with neuronal membranes, regulate secondary structure and neurotoxicity, and cause Alzheimer's disease. β Amyloid(28-35) human has anisotropic effects on the acidic phospholipid DPH, resulting in enhanced internal fluidity of lipid membrane bilayers.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-B0882S Edrophonium-d5 chloride
Edrophonium-d5 chloride is the deuterium labeled Edrophonium chloride (HY-B0882). Edrophonium chloride is a short-acting acetylcholinesterase (AChE) inhibitor. Edrophonium chloride has Ki values of 0.2, 0.2, and 0.4 μM and IC50 values of 0.2, 0.05, and 0.5 μM for AChE in human erythrocytes, purified calf forebrain, and purified octopus brain, respectively. Edrophonium chloride can be used to detect early digitalis toxicity and in the study of myasthenia gravis.
Isotope-Labeled Compounds   Cholinesterase (ChE)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-N15452 Eseramine
Eseramine is a weak acetylcholinesterase inhibitor with an IC50 value of 9300 nM. Eseramine is promising for research of diseases involving the regulation of acetylcholinesterase, such as glaucoma, myasthenia gravis, and protection against organophosphate poisoning.
Cholinesterase (ChE)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-125738 Obscurolide A1
Obscurolide A1 is a Phosphodiesterase (PDE) inhibitor (IC50=8 mM) that can be obtained from Streptomyces viridochromogenes culture. Obscurolide A1 has the potential to study neurological and inflammatory diseases.

Source: Streptomyces

Phosphodiesterase (PDE)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-D2266 FluoBar1
FluoBar1 is an imaging fluorescence probe modified by a barbiturate ligand with fluorescent coumarin. FluoBar1 can monitor L-type voltage-gated calcium channels (LTCC) in living cells in real time for the study of neurological diseases .
Fluorescent Dye  
Neurological, Eye or Ear Disease  
/
HY-P992380 IBC-Ab002
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease.

Species: Human

PD-1/PD-L1  
Alzheimer's Disease  
/
HY-N6703S ar-Turmerone-d3
ar-Turmerone-d3 is the deuterium labeled ar-Turmerone. ar-Turmerone ((+)-ar-Turmerone) is an orally active and major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-Turmerone induces apoptosis in U937 cells. ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation in vitro and in vivo, and can be used for various neurologic disorders study.
Isotope-Labeled Compounds   Apoptosis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P5854 Aa1 toxin
Aa1 toxin, a neurotoxic peptide that can be obtained from the venom of Androctonus australis Garzoni, is a specific potassium channel blocker. Aa1 toxin can be used in the study of neurological diseases.
Potassium Channel  
Neurological, Eye or Ear Disease  
/
HY-P5835 δ-Dendrotoxin
δ-Dendrotoxin is a K+ channel blocker that can be obtained from the venom of the black mamba snake. δ-Dendrotoxin can be used in the study of neurological diseases.
Potassium Channel  
Neurological, Eye or Ear Disease  
/
HY-W854549 Heparin pentasaccharide
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events.
Factor Xa  
Blood or Cardio-cerebrovascular Disease  
/
HY-N6619A Lycoramine
Lycoramine is a blood-brain barrier-penetrating Acetylcholinesterase inhibitor and Galanthamine (HY-76299) derivative. Lycoramine induces Amyloid-beta plaque clearance. Lycoramine induces reversal of cognitive decline and memory improvement. Lycoramine can be used for research on Alzheimer's disease and myasthenia gravis.
Cholinesterase (ChE)   Amyloid-β   Drug Derivative  
Alzheimer's Disease   Myasthenia gravis  
/
HY-N21625 Pleioside B
Pleioside B is a flavonoid glycoside found in the leaves of Pleioblastus amarus and acts as a B lymphocyte stimulator. Pleioside B stimulates the proliferation of murine B lymphocytes in vitro. Pleioside B can be used in research on immune-related diseases.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-N12041 Axl-IN-16
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression.

Source: Hericium erinaceus,Monascus

TAM Receptor   HIF/HIF Prolyl-Hydroxylase  
Cancer  
/
HY-P5448 MOG (92–106), mouse, rat
MOG (92-106), mouse, rat is a 15-peptide encephalitogenic epitope composed of amino acid residues 92-106 of myelin oligodendrocyte glycoprotein (MOG). MOG (92-106), mouse, rat serves as an I-As-restricted CD4+ T cell antigen. MOG (92-106), mouse, rat also induces extensive B cell responses against secondary myelin antigens such as MBP and PLP. MOG (92-106), mouse, rat is applicable to studies on multiple sclerosis, EAE, autoimmune demyelination, and antigen-specific T/B cell responses.
Endogenous Metabolite   MHC  
Experimental Autoimmune Encephalomyelitis   Multiple Sclerosis   Experimental Autoimmune Encephalomyelitis  
/
HY-P991590 1D09C3
1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL).

Species: Human

MHC   Apoptosis   JNK   Reactive Oxygen Species (ROS)  
Cancer  
/
HY-W704786 Prilocaine Hydrochloride-d7
Prilocaine Hydrochloride-d7 is the deuterium labeled Prilocaine hydrochloride (HY-B0137A). Prilocaine hydrochloride, an amino amide, is a Na/K-ATPase inhibitor. Prilocaine has neurotoxic effects.
Isotope-Labeled Compounds   Na+/K+ ATPase  
Neurological, Eye or Ear Disease  
/
HY-B0835S Fenobucarb-d3
Fenobucarb-d3 is the deuterium labeled Fenobucarb. Fenobucarb is a carbamate insecticide. Fenobucarb induces zebrafish developmental neurotoxicity through pathways involved in inflammation, oxidative stress, degeneration and apoptosis. Fenobucarb is a possible risk factor to cardiovascular and cerebrovascular systems in animals.
Isotope-Labeled Compounds   Apoptosis   Reactive Oxygen Species (ROS)   Caspase   Cholinesterase (ChE)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-W752907 Glufosinate-d8
Glufosinate-d8 is the deuterium labeled Glufosinate (HY-W019870A). Glufosinate, a phosphinic acid analogue of glutamic acid, is a herbicide which is converted by plant cells into PT (L-phosphinothricin). Glufosinate exerts neurotoxic activity.
Isotope-Labeled Compounds   Herbicide  
/
HY-B1637S Ditiocarb-d10 sodium
Ditiocarb-d10 sodium (Sodium diethyldithiocarbamate-d10) is the deuterium labeled Ditiocarb sodium (HY-B1637). Ditiocarb sodium (Sodium diethyldithiocarbamate) is an orally active copper reagent. Ditiocarb sodium exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium can be used in the research of tumors, inflammatory, and immune-related diseases.
Isotope-Labeled Compounds   HIV   Biochemical Assay Reagents  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-W321446 Dansyl ethylenediamine
Dansyl ethylenediamine is a fluorescent probe. Dansyl ethylenediamine can be used for synthesis of protein-imprinted polymers which is capable of specific transduction of protein binding events into fluorescent signal change.
Fluorescent Dye  
/
HY-P10680 TFE-IDAtp1-LinA
TFE-IDAtp1-LinA is a highly potent amphiphilic carrier, containing a trifluoroethyl-iminodiacetic acid analog of Stp. TFE-IDAtp1-LinA, formed nanoparticles with Cas9 RNP/ssDNA, achieved enhanced green fluorescent protein knockouts with an ED50 of 0.38 nM Cas9/sgRNA ribonucleoproteins (RNP).
Liposome  
/
HY-W718815 Novaluron-d3-1
Novaluron-d3-1 is the deuterium labeled Novaluron (HY-17519). Novaluron is a chemical with?insecticide?properties, an insect growth regulator, and has adverse effects on mouse sperm.
Isotope-Labeled Compounds   Insecticide   Environmental Pollutants  
Infection  
/
HY-107803 Geranium oil
Geranium oil serves as a partial agonist for estrogen receptor (ER), enhancing both the cytotoxicity induced by Tamoxifen (TMX) (HY-13757A) in GT1-7 cells and the adverse effects of TMX on the central nervous system. Geranium oil can be utilized in the research of neurological disorders such as dementia.
Estrogen Receptor/ERR  
Neurological, Eye or Ear Disease  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-101888R Cresyl Violet acetate (Standard)
Cresyl Violet acetate (Standard) is the analytical standard of Cresyl Violet acetate (HY-101888). This product is intended for research and analytical applications. Cresyl Violet acetate is a dye, which can be used to stain neurons.
Fluorescent Dye   Reference Standards  
/
HY-101878R Texas Red (Standard)
Texas Red (Standard) is the analytical standard of Texas Red (HY-101878). This product is intended for research and analytical applications. Texas Red (Sulforhodamine 101) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations.
Fluorescent Dye   Reference Standards  
/
HY-P991766 Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57)
Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57) reacts with the E2 protein of the Venezuelan equine encephalitis virus (VEEV). Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57) inhibits VEEV attachment to Vero cells, viral egress, viral fusion, and LDLRAD3-D1-Fc binding. Recommend Isotype Controls: Mouse IgG2c kappa, Isotype Control (HY-P99981).

Species: Virus

Flavivirus  
Infection  
/
HY-P990819 Anti-Rat CD28 Antibody (JJ316)
Anti-Rat CD28 Antibody (JJ316) is a mouse-derived agonistic IgG1 κ type antibody, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ316) can induce T cell proliferation. Anti-Rat CD28 Antibody (JJ316) can be used for the researches of inflammation, immunology and neurological disease, such as experimental autoimmune encephalomyelitis (EAE) and graft-versus-host disease (GvHD).

Species: Rat

CD28  
Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-12388 N-Desmethyl clomipramine
Desmethylclomipramine (Norclomipramine) is a metabolite of Clomipramine (HY-B0457A) and can be used for neurological research.
Drug Metabolite  
Neurological, Eye or Ear Disease  
/
HY-P990793 Anti-Mouse CD28 Antibody (D665)
Anti-Mouse CD28 Antibody (D665) is a mouse-derived agonistic IgG1 κ type antibody, targeting to mouse CD28. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for the researches of neurological disease, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).

Species: Mouse

CD28  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-N5077R Sinapine (Standard)
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
Reference Standards   Cholinesterase (ChE)   P-glycoprotein  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-B0277R Vidarabine (Standard)
Vidarabine (Standard) (Ara-A (Standard)) is the analytical standard of Vidarabine (HY-B0277). This product is intended for research and analytical applications. Vidarabine (Ara-A) is a Purine nucleoside derivative and Antiviral agent. The triphosphate derivative of Vidarabine competitively inhibits DNA polymerase, incorporates into the terminus of elongating DNA molecules, and interferes with the early steps of viral DNA synthesis. Vidarabine inhibits the replication of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus and vaccinia virus, reduces viral shedding, and accelerates skin healing. Vidarabine is metabolized to arabinosyl hypoxanthine, causes minimal impairment of corneal wound healing in rabbit models, and is associated with recurrence of herpes simplex encephalitis. Vidarabine can be used in the research of herpetic keratoconjunctivitis, herpes simplex encephalitis, herpetic uveitis, and chronic active hepatitis associated with hepatitis B virus.
Reference Standards   Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis   HSV   VZV   CMV   EBV  
Cytomegalovirus Infection   HSV Infection  
/
HY-12388S N-Desmethyl clomipramine-d7
N-Desmethyl clomipramine-d7 (Desmethylclomipramine-d7) is deuterium labeled N-Desmethyl clomipramine. Desmethylclomipramine (Norclomipramine) is a metabolite of Clomipramine (HY-B0457A) and can be used for neurological research.
Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-32350S1 Ercalcitriol-d3
Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
Isotope-Labeled Compounds   VD/VDR   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-W011086R Tri-O-tolyl phosphate (Standard)
Tri-O-tolyl phosphate (Tri-O-cresyl phosphate; TOTP) (Standard) is an analytical standard of Tri-O-tolyl phosphate (HY-W011086). This product is intended for research and analytical applications. Tri-O-tolyl phosphate is an aryl phosphate compounds commonly utilized as flame retardants and lubricant additives across various industrie. Tri-O-tolyl phosphate has neurotoxicity and reproductive toxicity, decreasing cell viability, inhibiting cell proliferation, triggering cell cycle arrest, induceing apoptosis, causing mitochondrial dysfunction, disrupts calcium homeostasis.
Biochemical Assay Reagents   Reference Standards   Apoptosis  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-121892 (Z)-KC02
(Z)-KC02 is an inhibitor of ABHD16A, the phosphatidylserine (PS) lipase that produces lyso-PS. Lysophosphatidylserine (lyso-PS) is a signaling lipid that regulates immune and neurological processes. It is associated with several neurological disorders such as retinitis pigmentosa and cataracts (PHARC). (Z)-KC02 depletes lyso-PS in lymphoblasts from PHARC subjects. (Z)-KC02 also reduces lyso-PS and lipopolysaccharide-induced cytokine production in macrophages and modulates lyso-PS metabolism in vivo.
TNF Receptor  
Neurological, Eye or Ear Disease  
/
HY-P5642A Retrocyclin-101 TFA
Retrocyclin-101 (RC-101) TFA is an artificially synthesized, cyclic-structured θ-defensin, a broad-spectrum agent with antimicrobial (covering viruses, bacteria, and fungi) activity and anti-inflammatory activity. Retrocyclin-101 TFA can inhibit the serine protease activity of ZIKV NS2B-NS3, with an IC50 of 7.20 μM. Retrocyclin-101 TFA has significant inhibitory activity against HIV, SARS-CoV-2, flaviviruses, influenza viruses, HSV-1/2, Staphylococcus aureus, etc. Retrocyclin-101 TFA inhibits the signal transduction mediated by TLR4 and TLR2, reducing the expression of pro-inflammatory cytokines.
HIV   SARS-CoV   Influenza Virus   Flavivirus   HSV   Bacterial   Fungal   Toll-like Receptor (TLR)   Ser/Thr Protease  
Inflammation or Immune System Disease   Viral Infection   Bacterial Infection   Fungal Infection  
/
HY-W127493 1-Hexacosanol
1-Hexacosanol can be used as an inhibitor of acetylcholinesterase (AChE). 1-Hexacosanol has larvicidal activity and can inhibit the acetylcholinesterase activity of Culex quinquefasciatus, Aedes aegypti and Chironomus riparius, exerting neurotoxic effects.
Biochemical Assay Reagents  
Infection  
/
HY-W025830 2-(1-(2-Amino-2-oxoethyl)cyclohexyl)acetic acid
2-(1-(2-Amino-2-oxoethyl)cyclohexyl)acetic acid has neurological properties and can be used to study the structure and function of proteins and enzymes, as well as protein-protein interactions. 2-(1-(2-Amino-2-oxoethyl)cyclohexyl)acetic acid can also be used to study the structure and function of compounds.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-B1315S1 Carbaryl-d7
Carbaryl-d7 is the deuterium labeled Carbaryl (HY-B1315). Carbaryl is the inhibitor for acetylcholinesterase that inhibits the degradation of acetylcholine in the synaptic cleft, leads to the accumulation of acetylcholine and causes neurotoxicity. Carbaryl can be used as an insecticide.
Isotope-Labeled Compounds   Insecticide   Cholinesterase (ChE)   Reactive Oxygen Species (ROS)   Apoptosis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P1517 β-Amyloid (31-35)
β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-13010S Laquinimod-d5
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research.
Isotope-Labeled Compounds   NF-κB   Apoptosis  
Inflammation or Immune System Disease  
/
HY-P990135 Anti-Rat CD4 Antibody (OX-38)
Anti-Rat CD4 Antibody (OX-38) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to rat CD4. Anti-Rat CD4 Antibody (OX-38) can deplete CD4+ cells. Anti-Rat CD4 Antibody (OX-38) can be used for the researches of immunology and infection, such as borna disease and transplantation.

Species: Rat

Transmembrane Glycoprotein  
Infection   Inflammation or Immune System Disease  
/
HY-P991611 ART5803
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis.

Species: Human

iGluR  
Inflammation or Immune System Disease  
/
HY-P990778 Xirestomig
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs).

Species: Human

TNF Receptor   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-103283 Neuromedin C (porcine)
Neuromedin C porcine (GRP, 18-27, porcine) is a bombesin-like neuropeptide that can be obtained from porcine spinal cord. Neuromedin C porcine exhibits a potent contractile activity on rat uterus in the characteristic manner of bombesin. Neuromedin C porcine has research potential for neurological-related diseases.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-B0739AR Citicoline sodium (Standard)
Citicoline sodium (Standard) is the analytical standard of Citicoline sodium. This product is intended for research and analytical applications. Citicoline sodium is an endogenous intermediate in the synthesis of phosphatidylcholine which is a component of cell membranes. Citicoline sodium inhibits reactive oxygen species (ROS) and apoptosis. Citicoline sodium can be used for neurological disease and hearing loss study.
Reference Standards   Endogenous Metabolite   Apoptosis   Reactive Oxygen Species (ROS)   Caspase  
Cancer   Neurological, Eye or Ear Disease  
/
HY-N7027 Macrozamin
Macrozamin is a major constituent principle of Cycads. Macrozamin has carcinogenic, mutagenic, teratogenic and neurotoxic properties.
Others  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P5766A AChRα(97-116) TFA
AChRα(97-116) TFA, a peptide, can be used to induce experimental autoimmune myasthenia gravis (EAMG)
nAChR  
Metabolic or Endocrine Disease  
/
HY-P990818 Anti-Rat FcRn heavy chain heterodimers Antibody (1G3)
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Rat

Fc Receptor (FcR)  
Inflammation or Immune System Disease  
/
HY-P99895 Rulonilimab
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity.

Species: Human

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-N6579 Arvenin I
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
p38 MAPK   Mitochondrial Metabolism  
Cancer  
/
HY-69166 1H-Indazol-5-ol
1H-Indazol-5-ol is a porcine DAAO inhibitor with an IC50 value of 2.03 μM. 1H-Indazol-5-ol can be used in the research of neurological disorders.
Amino Acid Oxidase  
Neurological, Eye or Ear Disease  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-P10862 AH-D peptide
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50
values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-136213 Endoplasmic reticulum dye 1
Endoplasmic reticulum dye 1 is a rhenium (I)-based luminescent, membrane-permeable cell imaging reagent with low cytotoxicity, photobleaching resistance, and suitability for multicolor imaging. Endoplasmic reticulum dye 1 localizes to the nuclear membrane, endoplasmic reticulum, and nucleoplasmic reticulum in live cells. Endoplasmic reticulum dye 1 enables detection of exocytosis events, dynamic changes in nuclear membrane-derived phagosomes, and vesicle trafficking processes.
Fluorescent Dye  
/
HY-P5807A Cn2 toxin TFA
Cn2 toxin TFA (β-Mammal toxin Cn2 TFA) is a single-chain β-scorpion neurotoxic peptide that is the main toxin in scorpion venom. Cn2 toxin (TFA) specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6.
Sodium Channel  
Neurological, Eye or Ear Disease  
/
HY-D2871 DAyne
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-B0739AS Citicoline-d9 sodium
Citicoline-d9 (Cytidine diphosphate-choline-d9) sodium is the deuterium labeled Citicoline sodium (HY-B0739A). Citicoline sodium is an endogenous intermediate in the synthesis of phosphatidylcholine which is a component of cell membranes. Citicoline sodium inhibits reactive oxygen species (ROS) and apoptosis. Citicoline sodium can be used for neurological disease and hearing loss study.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   Reactive Oxygen Species (ROS)   Caspase  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P991114 Adezkibart
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases.

Species: Human

FLT3  
Inflammation or Immune System Disease  
/
HY-N2511 Trimyristin
Trimyristin is an orally active compound. Trimyristin can be isolated from the seeds of nutmeg (Myristica fragrans). Trimyristin inhibits the activities of acetylcholinesterase (AChE), ACP and ALP, with IC50 values of 0.11, 0.16 and 0.18 mM, respectively. Trimyristin exerts competitive-noncompetitive inhibition on acetylcholinesterase, uncompetitive inhibition on ACP, and competitive/noncompetitive inhibition on ALP. Trimyristin restores the downregulated acetylcholinesterase concentration in the cerebral cortex of rats exposed to sodium arsenite. Trimyristin can be used in studies related to fascioliasis and neurotoxicity.
Cholinesterase (ChE)   Phosphatase  
Neurological, Eye or Ear Disease   Parasitic Infection  
/
HY-50723 3-Methylxanthine
3-Methylxanthine is a blood-brain barrier-permeable cyclic GMP phosphodiesterase inhibitor, with an IC50 of 920 μM against guinea pig cyclic GMP phosphodiesterase. 3-Methylxanthine relaxes the spontaneous tension of isolated guinea pig tracheal smooth muscle preparations. Through a DRD1-dependent pathway, 3-Methylxanthine upregulates the expression of γH2AX and activated caspase-3, downregulates the expression of Bcl-2, and enhances Cisplatin-induced apoptosis (apoptosis) in ovarian cancer cells both in vitro and in vivo. 3-Methylxanthine induces clonic convulsions in the central nervous system. 3-Methylxanthine is the major metabolite of Theophylline (HY-B0809). 3-Methylxanthine can be used in studies related to ovarian cancer and neurotoxic convulsions.
Endogenous Metabolite   Phosphodiesterase (PDE)   Caspase   Bcl-2 Family   Apoptosis  
Neurological, Eye or Ear Disease   Ovarian Cancer  
/
HY-185057 S-D-Lactoylglutathione
S-D-Lactoylglutathione (S-Lactylglutathione; (R)-S-Lactoylglutathione) is a multifunctional metabolic intermediate of the glyoxalase system. S-D-Lactoylglutathione activates K+ efflux in bacteria by displacing inhibitory glutathione from KefGB channels, thereby acidifying the cytoplasm. In eukaryotic cells, S-D-Lactoylglutathione mediates S-glutathionylation as a substrate of glyoxalase 2. S-D-Lactoylglutathione serves as a sensitive metabolic biomarker for neodymium nitrate neurotoxicity; when used in combination with MSCs-exo, it upregulates glutathione levels, downregulates lactate dehydrogenase and Glo2 levels, and inhibits cellular inflammatory responses and pyroptosis. S-D-Lactoylglutathione can be used in research related to prostate cancer, breast cancer, non-small cell lung cancer, sepsis-associated encephalopathy, and neurotoxicity.
Glyoxalase (GLO)   Endogenous Metabolite   Potassium Channel  
Breast Cancer   Prostate Cancer   Non-Small Cell Lung Cancer   Neurotoxic Agent  
/
HY-P99959 Unasnemab
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments.

Species: Human

TGF-β Receptor  
Neurological, Eye or Ear Disease  
/
HY-P99166 Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Species: Human

PD-1/PD-L1   CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-120967 (2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%
(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer.
p38 MAPK   Akt   Interleukin Related  
Cancer  
/
HY-P4086 Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)
Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is a cell-penetrating peptide that is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) binds to
nAChR on neuronal cells to mediate receptor-mediated endocytosis and targeted siRNA delivery. Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) protects complexed siRNA from degradation, enhances transcellular siRNA delivery in neuronal cells, and promotes efficient, pecific gene silencing. Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) can be used for the researches of neurological disease and cancer.
RABV   nAChR  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P990042 Gotistobart
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P990690 Volrustomig
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer.

Species: Human

PD-1/PD-L1   CTLA-4  
Gastric Cancer   Liver Cancer   Cervical Cancer   Non-Small Cell Lung Cancer  
/
HY-P99638 Gefurulimab
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-P990569 CM-24
CM-24 (MK-6018) is a highly selective humanized monoclonal antibody targeting CEACAM1/CD66a. CM-24 binds to the N-terminal domain of CEACAM1, blocks the CEACAM1-CEACAM1 interaction, relieves the co-inhibitory effect on CEACAM1-positive lymphocytes, and enhances the cytotoxic activity of TIL, LAK and NK cells against CEACAM1-positive tumor cells. CM-24 can be used in studies related to tumor immunology, tumor metastasis and thrombosis. For the isotype control of CM-24, refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-P99950 Evorpacept
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
CD47  
Leukemia/Lymphoma/Myeloma   Luminal Breast Cancer  
/
HY-P99359 Elezanumab
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism.

Species: Human

TGF-beta/Smad  
Metabolic or Endocrine Disease   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-P990789 Anti-Mouse CTLA-4 Antibody (9H10)
Anti-Mouse CTLA-4 Antibody (9H10) is a kind of syrian hamster IgG antibody inhibitor, targeting to CTLA-4. Anti-Mouse CTLA-4 Antibody (9H10) binds mouse CTLA-4 and blocks the interaction between CTLA-4 and its ligand. Anti-Mouse CTLA-4 Antibody (9H10) shows potent anti-tumor effect in various tumor models, such as breast and colon cancer.

Species: Mouse

CTLA-4  
Breast Cancer   Prostate Cancer  
/
HY-N7368 Hibifolin
Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (Ki = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC50 = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A).
Adenosine Deaminase   Bacterial   Caspase  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Bacterial Infection  
/
HY-P990302 Anti-Human/Rat/Fish AChR Antibody (Mab35)
Anti-Human/Rat/Fish AChR Antibody (Mab35) is an anti-human/rat/fish AChR IgG1 monoclonal antibody. Anti-Human/Rat/Fish AChR Antibody (Mab35) can attack the AChR of neuromuscular junctions. Anti-Human/Rat/Fish AChR Antibody (Mab35) can be used for the construction of myasthenia gravis models.

Species: Human/Rat/Fish

nAChR  
Myasthenia gravis  
/
HY-P991127 Claseprubart
Claseprubart (DNTH103) is an inhibitor targeting C1s of the complement system and an inhibitor of the C1 component of the complement cascade. Claseprubart is in phase 2 clinical evaluation. Claseprubart has application potential in research related to multifocal motor neuropathy and generalized myasthenia gravis.

Species: Human

Complement System  
Myasthenia gravis  
/
HY-P0325 V5 Epitope Tag Peptide TFA
V5 Epitope Tag Peptide TFA is a tag peptide derived from a small epitope present on the P and V proteins of the paramyxovirus of simian virus 5. V5 Epitope Tag Peptide TFA can be used for protein separation and purification, and competitive elution with target proteins.
Biochemical Assay Reagents  
/
HY-P5911 GluN1(359-378)
GluN1 (359-378) is an anti-N-methyl-D-aspartate receptor (NMDAR) peptide. GluN1 (359-378) can cross the blood-brain barrier. GluN1 (359-378) can be used to study anti-NMDAR encephalitis therapy targeting the immune system.
iGluR  
Inflammation or Immune System Disease  
/
HY-P991628 SSGJ-707
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1 signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer.

Species: Human

PD-1/PD-L1   VEGFR  
Colorectal Cancer   Small Cell Lung Cancer   Non-Small Cell Lung Cancer  
/
HY-P5766 AChRα(97-116)
AChRα(97-116) is a synthetic peptide corresponding to the 97-116 region of the rat acetylcholine receptor α-subunit, and also an inducer of autoimmune diseases. AChRα(97-116) can be used in studies related to experimental autoimmune myasthenia gravis.
nAChR  
Metabolic or Endocrine Disease  
/
HY-P99365 Ravulizumab
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Species: Human

Complement System  
Metabolic or Endocrine Disease  
/
HY-D1005A6 Poloxamer 124 (L44)
Poloxamer 124 L44 is a block polymer of polyoxyethylene and polyoxypropylene and a hydrophobic surfactant. Poloxamer 124 L44 causes eye irritation and exhibits oral toxicity in albino rats with an LD50 of 5 g/kg. Poloxamer 124 L44 has reversible adverse effects on triglyceride and cholesterol transport in the lymphatic system of rats. Poloxamer 124 L44 can form thermoreversible hydrogels and is used as a food additive and as a drug delivery vehicle in cosmetics, pharmaceuticals, and tissue engineering[1][2][3].
Environmental Pollutants   Biochemical Assay Reagents  
/
HY-P9986 Tiragolumab
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.

Species: Human

CD28  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P990706 Povetacicept
Povetacicept (ALPN-303) is an engineered Fc fusion protein containing the TACI domain, and acts as a dual APRIL/BAFF antagonist. The Kd value of Povetacicept for human BAFF is 59.3 pM, while its Kd value for human APRIL is 1.00 pM. Povetacicept reduces the activation, proliferation, differentiation and survival of B cells, and inhibits the production of immunoglobulins and autoantibodies. Povetacicept can be used in research related to autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis and myasthenia gravis.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P5912 GluN1(356-385)
GluN1 (356-385) is a polypeptide targeting NMDAR GluN1. GluN1 (356-385) induces the production of autoantibodies, which reduce the density of cell surface NMDAR clusters, impair long-term potentiation, and decrease NMDAR-mediated Ca2+ influx. As an immunogen, GluN1 (356-385) induces symptoms similar to anti-NMDAR encephalitis, including memory loss, in mice. GluN1 (356-385) can be used to establish a mouse model that mimics the pathogenesis of anti-NMDAR encephalitis. GluN1 (356-385) is applicable to research related to anti-NMDAR encephalitis.
iGluR   Calcium Channel  
Neurological, Eye or Ear Disease  
/
HY-P99009 Batoclimab
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease.

Species: Human

Fc Receptor (FcR)  
Autoimmune Disease  
/
HY-P9918 Tremelimumab
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-147305 Efgartigimod alfa
Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research.

Species: Human

Fc Receptor (FcR)  
Myasthenia gravis   Platelet Disease  
/
HY-P71819 ELAVL3 Protein, Human (P.pastoris, His)
ELAVL3 protein is an RNA-binding protein that specifically binds to the ARE sequence in target mRNA, including VEGF. It may also interact with polyA tracts through its RRM3. ELAVL3 Protein, Human (P.pastoris, His) is the recombinant human-derived ELAVL3 protein, expressed by P. pastoris , with N-His labeled tag.

Species: Human; Source: P. pastoris

/
HY-P85158 FER Antibody (YA4850)
FER Antibody (YA4850) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to FER.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-K3014D Bi-27 Serum-free Supplement (50×), Antioxidant-Free

MCE Bi-27 Serum-free Supplement (50×), Antioxidant-Free is a customized neuronal culture supplement developed by removing antioxidants components (such as vitamins, superoxide dismutase, catalase, etc.) from the standard Bi-27 formulation. It is specifically designed for investigating the roles of reactive oxygen species (ROS) in aging, cytotoxicity, apoptosis, and chronic neurological diseases. This formulation provides a stable culture environment for mechanistic studies without the interference of exogenous antioxidants.

Cell Biology Cell Culture Cell Culture Supplements

/

Keywords

neurologic immune-related adverse events | immune checkpoint inhibitors | encephalitis | demyelination | myasthenia gravis | neurotoxicity